Tekmira Pharmaceuticals Corporation (TKMR)
Add to Watchlists Create an AlertTKMR Key Stats
| Income Statement | |
| Revenue TTM | 14.08M |
| Revenue Quarterly YoY Growth | 6.43% |
| EPS Diluted TTM | 1.694 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | 29.98M |
| Profitability | |
| Gross Profit Margin Quarterly | -86.32% |
| Profit Margin Quarterly | |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 68.00M |
| Enterprise Value | 22.26M |
| PE Ratio TTM | 2.792 |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 1.661 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow | 40.75M |
| Return on Equity | 270.9% |
TKMR News
- Tekmira Announces Election of Directors noodls May 17
- Tekmira Presents LNP Technology Innovations at Scientific Symposium GlobeNewswire May 15
- Tekmira Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcrip... May 14
- Tekmira Provides Corporate Update and Announces First Quarter 2013 Results GlobeNewswire May 14
- Tekmira Conference Call and Webcast Advisory: Corporate Update and First Quarter... May 9
- Tekmira is on Track to Advance TKM-Ebola Program - Analyst Blog Zacks May 9
- Tekmira Recieves $140M Government Contract for TKM-Ebola Program Benzinga May 8
- Tekmira Provides Update on U.S. Government Sponsored TKM-Ebola Program GlobeNewswire May 8
- The Beginning Of A Shift At Tekmira: From Focus On Delivery, To Therapy Apr 23
- Early-Stage Clinical Data Highlights From AACR 2013 Apr 17
TKMR Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Tekmira Pharmaceuticals Corporation is up 122.1% over the last year vs S&P 500 Total Return up 28.68%, Alnylam Pharmaceuticals up 176.7%, and DelMar Pharmaceuticals up 0.00%.
TKMR Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these TKMR related companies
Pro Ratings for TKMR
Pro Report PDF for TKMR
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download TKMR Pro Report PDF
Pro Strategies Featuring TKMR
Did Tekmira Pharmaceuticals Corporation make it into our Pro Portfolio Strategies?
TKMR Profile
Sector: Healthcare
Industry: Biotechnology
Other TKMR Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| TKMR | 4.73 | -0.09 | -1.87% | 68.00M |
